{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-011681","form_type":"8-K","ticker":"DNTH","cik":"0001690585","company_name":"Dianthus Therapeutics, Inc. /DE/","filed_at":"2024-01-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.132570+00:00","generated_at":"2026-06-06T20:42:56.431263+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Dianthus Therapeutics raises $230M in PIPE financing at $12.00/share","bullets":["PIPE gross proceeds ~$230M from 14.5M common shares at $12.00 and 4.7M pre-funded warrants at $11.999.","New and existing investors participating: Bain Capital Life Sciences, RA Capital, Avidity Partners, and others.","Closing expected Jan 24, 2024; proceeds for R&D, working capital, and potential business development.","Placement agents: Jefferies, Evercore ISI, Stifel, Guggenheim Securities, Raymond James."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-011681","json":"https://secwatch.observer/filing/0001193125-24-011681.json","markdown":"https://secwatch.observer/filing/0001193125-24-011681.md","text":"https://secwatch.observer/filing/0001193125-24-011681.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1690585/000119312524011681/0001193125-24-011681-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1690585/000119312524011681/d699582d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T20:42:56.431263+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f0fbef91d1b9c073265d90c45f3ad165d0f2a39e","claim":"Dianthus Therapeutics, Inc. /DE/ entered into Registration Rights Agreement with Institutional and accredited investors valued at Registration Rights Agreement for resale registration (effective 2024-01-22).","evidence_excerpt":"Also on January 22, 2024, the Company entered into a Registration Rights Agreement (the \"Registration Rights Agreement\") with the Purchasers, which provides that the Company will register the resale of the Common Shares and the Pre-Funded Warrant Shares.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1690585/000119312524011681/0001193125-24-011681-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Institutional and accredited investors"},{"label":"Value","value":"Registration Rights Agreement for resale registration"},{"label":"Effective","value":"2024-01-22"}],"fact_type":"material_agreement"},{"claim_id":"fda4092b4e42da2fb98d01442bed8221e8c10e04","claim":"Dianthus Therapeutics, Inc. /DE/ entered into Securities Purchase Agreement with Institutional and accredited investors valued at 230,000,000 USD (effective 2024-01-22).","evidence_excerpt":"On January 22, 2024, Dianthus Therapeutics, Inc., a Delaware corporation (the \"Company\"), entered into a Securities Purchase Agreement (the \"Purchase Agreement\") for a private placement (the \"Private Placement\") with certain institutional and accredited investors (each, a \"Purchaser\" and collectively, the \"Purchasers\").","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1690585/000119312524011681/0001193125-24-011681-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Institutional and accredited investors"},{"label":"Value","value":"230,000,000 USD"},{"label":"Effective","value":"2024-01-22"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}